Press Release

November 4, 2026 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Sub: Press Release Ref.: Disclosure under regulation 30 of SEBI (Listing Regulations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”) Pursuant to the provisions of regulation 30 of the Listing Regulations, please find enclosed the press release dated November 4, 2026, to be published in the newspapers relating to unaudited financial results for the quarter / half year ended on September 30, 2026. Please find the same in order. Yours faithfully, For, Zydus Lifesciences Limited Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS7063 Encl.: As above Zydus Lifesciences Limited Financial Performance for Q 2 & H1 FY2 7 4th November 202 6, Ahmedabad, India Zydus Lifesciences L td. announced its unaudited consolidated financial results for the quarter and half year ended September 30th, 2026. Key Financial Highlights Q2 FY2 7 Highlights • Revenue from operations at Rs. 79,096 mn, up 29% over last year . • Research & Development (R&D) investment s for the quarter stood at Rs. 6,573 mn (8.3% of revenues). • EBITDA for the quarter was Rs. 18,945 mn, down 6% y-o-y. EBITDA margin for the quarter stood at 24.0%. • Net Profit for the quarter was Rs. 9,255 mn, down 27% y-o-y. • Capex (organic) for the quarter was Rs. 4,655 mn. H1 FY2 7 Highlights • Revenue from operations at Rs. 1,59,266 mn, up 25% over last year . • Research & Development (R&D) investment s stood at Rs. 12,997 mn ( 8.2% of revenues). • EBITDA was Rs. 38,239 mn, down 7% y-o-y. EBITDA margin stood at 24.0%. • Net Profit was Rs. 18,859 mn, down 31% y-o-y. • Capex (organic) for the half year was Rs. 10,530 mn. • Net Debt to Equity ratio as on 30 th September, 202 6 was 0.19x while Net Debt to EBITDA stood at 0.62x at the end of September, 202 6. Consolidated Financial Results Q2 Q2 % Gr. Q1 % Gr. Rs. mn FY2 7 FY2 6 y-o-y FY2 7 q-o-q Revenue from Operations 79,096 61,232 29.2% 80,170 -1.3% EBITDA 18,945 20,158 -6.0% 19,294 -1.8% EBITDA margin (%) 24.0% 32.9% 24.1% PBT 12,617 16,942 -25.5% 13,691 -7.8% Net Profit 9,255 12,609 -26.6% 9,604 -3.6% H1 H1 % Gr. Rs. mn FY2 7 FY2 6 y-o-y Revenue from Operations 1,59,266 1,26,969 25.4% EBITDA 38,239 41,043 -6.8% EBITDA margin (%) 24.0% 32.3% PBT 26,308 36,492 -27.9% Net Profit 18,859 27,277 -30.9% Our Q2 performance reflects strong, all -round momentum, spearheaded by our branded businesses in India, International Markets and Wellness. Notably, the share of branded sales in the US has risen to 16%, underscoring our steady shift towards a more differentiated, specialty -led portfolio. We look forward to the approval and launch of Saroglitazar in the US, our first indigenously discovered NCE, which marks a pivotal point in our evolution. Anchored i n patient centricity and supported by robust quality syst ems, we remain committed to building long -term growth levers and enhancing returns for all our stakeholders. Dr. Sharvil Patel, Managing Director - Zydus Lifesciences Limited Q2 FY2 7 Business -wise Sales Performance (Consolidated) Q2 Q2 % Gr. Q1 % Gr. Rs. mn FY2 7 FY2 6 y-o-y FY2 7 q-o-q Pharma Business 64,075 52,473 22.1% 60,900 5.2% India Formulations 18,844 15,926 18.3% 18,158 3.8% North America Formulations 33,145 27,437 20.8% 30,979 7.0% IM Formulations 10,009 7,513 33.2% 9,735 2.8% APIs 1,485 1,472 0.9% 1,804 -17.7% Alliances & Others 592 125 373.6% 224 164.3% Consumer Wellness 11,223 6,374 76.1% 14,292 -21.5% MedTech 2,246 1,532 46.6% 2,828 -20.6% Consolidated Revenues 77,544 60,379 28.4% 78,020 -0.6% Q2 FY2 7 Consolidated business mix Q2 FY2 7 Pharma business mix Medtech North America Consumer Wellness Pharma Business Formulations 14% 83% 43% IM Formulations India Formulations APIs & Others H1 FY2 7 Business -wise Sales Performance (Consolidated) H1 H1 % Gr. Rs. mn FY2 7 FY2 6 y-o-y Pharma Business 1,24,975 1,08,574 15.1% India Formulations 37,002 31,118 18.9% North America Formulations 64,124 59,254 8.2% IM Formulations 19,744 14,778 33.6% APIs 3,289 3,047 7.9% Alliances & Others 816 377 116.4% Consumer Wellness 25,515 14,923 71.0% MedTech 5,074 1,552 226.9% Consolidated Revenues 1,55,564 1,25,049 24.4% H1 FY2 7 Consolidated business mix H1 FY2 7 Pharma business mix Medtech North America Formulations Consumer Wellness Pharma Business 41% IM Formulations 16% 13% India Formulations APIs & Others Q2 FY2 7 Business Updates Pharma Business India Formulations business • Registered revenues of Rs. 18,844 mn, up 18% y-o-y. The business accounted for 24% of consolidated revenues. Branded formulations business grew 19% y -o-y. • The business has consistently delivered above -market performance during the last 3 financial years and has maintained this momentum through the first half of current fiscal as well . • Secondary sales growth was 20% y-o-y with volume and new products accounting for around two -third of the total growth . • In terms of therapeutic performance, gained share in Cardiology, Diabetology, Respiratory, Dermatology, Gastro -Intestinal, Anti -infectives and in super specialty areas of Oncology and Nephrology. • Ranking improved in Cardiology, Diabetology Gastro -Intestinal and Anti -infective therapies while on the super specialty front, continued to retain leadership position in Oncology therapy. • Share of chronic and sub chronic portfolio has increased consistently over last several years and stood at 56.9%, an improvement of 450 bps over the last 4 years (Source: AWACS MAT September 2026 data). North America formulations business • Registered revenues of Rs. 33,145 mn, up 21% y-o-y and 7% q-o-q driven by sustained volume expansion in base business supplemented by continued scale - up of the US specialty business . The business accounted for 43% of consolidated revenues. • In constant currency terms, the business registered revenues of US$ 347 mn. • In the US generics space, filed 4 ANDAs , received approval for 12 ANDAs (including 2 tentative approvals ) and l aunched 5 new products during the quarter. • Launched the first generic version of Riociguat tablets in October 2026. • On the US specialty front, delivered strong sequential growth, driven by Rolvedon ® and continued momentum in the 505(b)(2) portfolio. International Markets formulations business • Registered revenues of Rs. 10,009 mn, up 33% y-o-y. The business accounted for 13% of consolidated revenues. • Growth was broad -based across markets, supported by strong underlying demand and focused execution. API business • Registered revenues of Rs. 1,485 mn, up 1% y -o-y. The business accounted for 2% of consolidated revenues. Alliances & Others • Registered revenues of Rs. 592 mn, up 374% y -o-y. The business accounted for 1% of consolidated revenues. Consumer Wellness business • Registered revenues of Rs. 11,223 mn, up 76% y -o-y. The business accounted for 14% of consolidated revenues. • Domestic business grew 29% y-o-y supported by sustained positive momentum across categories driven by steady urban recovery and improving rural demand . o Skin & hair care portfolio and food & nutrition portfolio registered 37% and 25% y-o-y growth respectively. • International business, including the Comfort Click business, delivered 12% growth on a like -to-like basis . MedTech business • Registered revenues of Rs. 2,246 mn, up 47% y -o-y. The business accounted for 3% of consolidated revenues. • The business is investing in enhancing its capabilities in focused segments which offer long -term growth potential to create differentiated value. Updates on Operations and Compliance • USFDA inspections at SEZ II, Ahmedabad and Moraiya formulations facilities concluded with one and five observations, respectively. The company is working closely with the regulator to address them expeditiously. [Showing first 8,000 characters — download PDF for full document]